RUNX1 and acute myeloid leukemia: Recently, novel RUNX1-targeted approaches showed promising results in a murine AML model and may pave the way to future opportunities to address refractory EM based on genetic data.18 Furthermore, the immune checkpoint inhibitor ipilimumab was able to induce complete responses in single cases of relapsed AML patients with EM after alloHCT, making it an attractive molecule for further investigations.19